Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2021-02-12 18:23:48
Reporting Period:
Accepted Time:
2021-02-12 18:23:48
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
886163 Ligand Pharmaceuticals Inc LGND Pharmaceutical Preparations (2834) 770160744
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1392029 C Todd Davis 3911 Sorrento Valley Boulevard, Ste 110
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-10 5,083 $213.14 47,678 No 4 S Direct
Common Stock Acquisiton 2021-02-11 2,474 $195.91 50,152 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-02-11 2,474 $0.00 2,474 $195.91
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2028-06-18 No 4 M Direct
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.84 to $214.58, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.